CN114404401A

CN114404401A - Application of escitalopram oxalate tablets in preparation of medicine for preventing and treating premature ejaculation

Info

Publication number: CN114404401A
Application number: CN202210279374.6A
Authority: CN
Inventors: 韩传恩; 徐楠
Original assignee: Individual
Current assignee: Individual
Priority date: 2022-03-22
Filing date: 2022-03-22
Publication date: 2022-04-29

Abstract

The invention discloses an application of escitalopram oxalate tablets in preparation of a medicine for preventing and treating premature ejaculation, which can be popularized and applied to clinical treatment of patients with premature ejaculation, is beneficial to delaying ejaculation of the patients, improving the satisfaction degree of the patients and the sexual life of the patients, promoting family harmony, and avoiding the defects of serious adverse reaction, high price and the like of the existing medicine for treating premature ejaculation, and has the advantages of safety, effectiveness, low price, quick response, convenience in popularization and application and the like.

Description

Application of escitalopram oxalate tablets in preparation of medicine for preventing and treating premature ejaculation

Technical Field

The invention relates to a new application of escitalopram oxalate tablets, in particular to an application of escitalopram oxalate tablets in preparation of a medicine for preventing and treating premature ejaculation.

Background

Escitalopram oxalate tablets, chemical name: s (+) -1- [3- (dimethylamino) propyl]-1- (4-fluorophenyl) -1, 3-dihydro-5-isobenzofurancarbonitrile oxalate; the molecular formula is as follows: c₂₀H₂₁FN₂O•C₂H₂O₄)。

Escitalopram oxalate is a therapeutic drug for mental system diseases, and the main application of escitalopram oxalate is that escitalopram oxalate can be used for treating depression, can improve the state of depression and has a certain effect on panic disorder. The escitalopram oxalate serving as SSRIs is widely applied to treatment of depression patients, can effectively improve clinical symptoms of the patients, improves the life quality of the depression patients, and is safe and reliable. Through literature search, no report on premature ejaculation treatment by using the medicine is available in China.

Disclosure of Invention

The technical problem to be solved by the invention is as follows: the application of the escitalopram oxalate tablet in preparing the medicine for preventing and treating premature ejaculation is provided, and the escitalopram oxalate tablet can treat premature ejaculation more effectively, more safely and more cheaply, so that the self-confidence of a patient is improved, and the sexual life quality of the patient is improved.

The active ingredients of the medicine of the invention are: escitalopram oxalate tablets;

chemical name: s (+) -1- [3- (dimethylamino) propyl ] -1- (4-fluorophenyl) -1, 3-dihydro-5-isobenzofurancarbonitrile oxalate;

the molecular formula is as follows: c₂₀H₂₁FN₂O•C₂H₂O_4;

Molecular weight: 414.43, respectively;

specification: 10 mg/tablet.

The invention brings the technical effects that: it has been found that 5-HT is an important neurotransmitter in the central nervous system, and that the incidence of premature ejaculation is inversely correlated with the level of 5-HT in serum. Antidepressants, such as 5-hydroxytryptamine reuptake inhibitors (SSRIs), are orally administered on demand and are characterized by rapid absorption, rapid onset of action, short half-life, rapid clearance in vivo and avoidance of accumulation. By inhibiting 5-HT transporters, the reuptake of 5-HT of a presynaptic membrane is effectively inhibited, the concentration of 5-HT in a synaptic cleft is increased, 5-HT2c and 5-HTla receptors of a postsynaptic membrane are activated, and the ejaculation threshold is increased, so that the function of delaying ejaculation is achieved. The invention can be popularized and applied to clinical treatment of premature ejaculation patients, is beneficial to delaying ejaculation of the patients, improves the satisfaction degree of the patients and the sexual life of the partners, promotes family harmony, avoids the defects of serious adverse reaction, high price and the like of the existing drugs for treating premature ejaculation, and has the advantages of safety, effectiveness, low price, quick effect, convenient popularization and application and the like.

Detailed Description

The following examples are intended to further illustrate, but not limit, the present invention.

The purpose is as follows: the clinical efficacy of the present invention for treating premature ejaculation was evaluated.

One, object and standard

1.1 study subjects 80 premature ejaculation patients were selected from the first civilian hospital of Shanqiu city from 3 months 2021 to 8 months 2021.

1.2 inclusion criteria: the diagnosis standard of the premature ejaculation in 2017 edition 'Chinese guidance for diagnosis and treatment of andrological diseases'; ② 22-50 years old; marrying for at least 4 months and regularly sexual life with the spouse; fourthly, the ejaculation latency time (IELT) in the vagina is less than or equal to 1 min; patients and their family members are informed and sign informed notice.

1.3 exclusion criteria: combining erectile dysfunction or other sexual dysfunction; ② secondary premature ejaculation; ③ partner sexual dysfunction; fourthly, the use of the medicine can be limited to chronic diseases or medicines; severe mental or psychological disorders.

1.4 rejection criteria: not meeting the inclusion standard; ② treatment is not completed according to plan; ③ treatment is stopped due to adverse reaction; the main indicators are lacking and the data is incomplete. The study was approved by the ethical committee of the first national hospital in commercial dune.

1.5 evaluation criteria: evaluation of effects (IELT): recording ejaculation latency before and 4 weeks after treatment for two groups of patients; ② premature ejaculation condition: the premature ejaculation condition of the patients is evaluated by a Premature Ejaculation Diagnostic Tool (PEDT), and the higher the score is, the higher the severity of the premature ejaculation of the patients is.

Second, research method

The patients to be observed were divided into 40 cases each of the treatment group and the control group at random according to the randomized numerical notation in the order of treatment. The medicine of the invention is taken 1 tablet/time and 1 time/day before sleep; the control group is administered with placebo (provided by pharmacy department of first people hospital in Shangqiu city, the ingredient is starch, the size and appearance are similar to those of the medicine of the invention) 1 tablet/time, 1 time/day before sleeping; both groups were treated for 1 treatment period of 4 weeks, with the patient being ordered into the same room 2 times a week (with an interval of about 3-4 days/time).

Thirdly, a statistical method: statistical analysis was performed using SPSS23.0 software. Metering data adoptiontChecking, expressed as mean + -standard deviation (' x + -s), and counting data using c²Checking;P<0.05 indicates that the difference is statistically significant.

Fourthly, the result

1. And (4) completing the condition: the treatment group had 1 case of dropping due to work movement and 3 cases of dropping due to unsuitable medication in driving and ascending work, and 36 cases in total were observed; the control group had 3 cases of loss of association and 37 cases of observation were completed (see the attached table for specific data: data of clinical observation of premature ejaculation).

2. Two groups of patients were compared for general condition: comparison of the differences in age and disease progression between the two groups of patients (A) and BP>0.05) The results are shown in Table 1.

TABLE 1 general comparison of two groups of patients (n, ` x. + -. s)

3. Comparison of IELT and PEDT scores before and after treatment in two groups of patients: before treatment, the IELT and PEDT scores of two groups of patients were compared, and the difference was not statistically significant (P _IELT=0.458、P _PEDT= 0.537) with comparability. After treatment, both groups of patients had significantly increased IELT compared to before treatment (t _{Treatment group}=6.159、P _{Treatment group}=0.000，t _{Control group}=4.490、P _{Control group}= 0.000), treatment group is better than control group: (P= 0.007); the PEDT scores of both groups of patients were significantly reduced compared to those before treatment (t _{Treatment group}=8.966、P _{Treatment group}=0.000，t _{Control group}=14.732、P _{Control group}= 0.000), treatment group is better than control group: (P= 0.048), the results are shown in table 2.

TABLE 2 comparison of IELT and PEDT scores before and after treatment in two groups of patients (n, ` x. + -. s)

4. The distribution of the post-treatment IELT improvement in two groups of patients was compared: after treatment, the IELT of the two groups of patients is prolonged to different degrees, the improvement of the patients of the treatment group is better than that of the control group in each section, and the difference has statistical significance (c ²=10.524，P= 0.005). Wherein, the comparison of the section with the time delay less than 1min shows that the contrast group is more than the treatment group, and the difference has statistical significance (c ²=7.448，P=0.006）；Delay 1-5 min section comparison, two groups of differences have no statistical significance: (c ²=0.113，P= 0.737); the comparison of the section with the time delay of more than 5min shows that the difference of the treatment group is more than that of the control group and has statistical significance (c ²=4.592，P= 0.032). The results are shown in Table 3

Table 3 two groups of patients IELT the distribution of improvement was compared (n,%)

And (4) conclusion:

the research result shows that the invention can greatly prolong the IELT time of the patient and reduce the PEDT score, thereby improving the ejaculation control power of the patient.

Data of clinical observation of premature ejaculation

Claims

1. Application of escitalopram oxalate tablets in preparation of medicine for preventing and treating premature ejaculation.